FLT3 and acute myeloid leukemia: In addition, using AML patient data, we showed that AML patients carrying FLT3-ITD have a significantly enhanced SLAP2 expression and FLT3-ITD positive AML patients with comparatively lower SLAP2 expression have intermediate or poor prognosis (Figure 5B).